Global Oncology | Specialty

The OncLive® Global Oncology condition center page is a comprehensive resource for clinical news and international expert insights on treatment of patients with cancer. This page features articles focused on ex-US regulatory news, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing global research in oncology care.

Neoadjuvant Pamiparib/Chemo Combo Leads to R0 Resections in Advanced Ovarian Cancer

August 6th 2025

Pamiparib with paclitaxel, carboplatin, and bevacizumab yields high complete cytoreduction rates, manageable safety in advanced ovarian cancer.

Rising Early‑Onset CRC Rates in Asia Underscore Global Trend in Incidence and Need for Coordinated Research Efforts

August 6th 2025

Evelyn Y. Wong, MD, discusses an analysis of a multiracial Asian cohort on the incidence of early‑onset colorectal cancer.

OncLive’s July EMA Regulatory Recap: Key EU Approvals in Oncology

August 6th 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.

EMA Grants PRIME Designation to BGB-16673 for Previously Treated Waldenström Macroglobulinemia

August 4th 2025

The BTK degrader BGB-16673 has received PRIME designation from the EMA for the treatment of patients with Waldenström macroglobulinemia.

EMA Grants Orphan Drug Designation to Nuvisertib for Myelofibrosis

August 2nd 2025

Nuvisertib has received orphan drug designation from the EMA for patients with myelofibrosis.

Brazilian Approval Is Sought for Tafasitamab Plus Rituxumab/Lenalidomide in R/R Follicular Lymphoma

August 1st 2025

A supplemental application has been submitted to Brazil’s health regulatory agency, seeking the approval of tafasitamab for follicular lymphoma.

China’s NMPA Accepts sNDA for Ivonescimab Plus Chemotherapy in Frontline Advanced Squamous NSCLC

July 31st 2025

Ivonescimab plus chemotherapy is under review in China for the frontline treatment of patients with advanced squamous non–small cell lung cancer.

Asciminib Nets Canadian Approval in Newly Diagnosed and Previously Treated Ph+ CML

July 31st 2025

Health Canada has expanded the approval of asciminib to include newly diagnosed and pretreated Ph-positive CML.

Novel LYN/BTK Dual Inhibitor Yields Durable Responses in Heavily Pretreated CLL/SLL

July 29th 2025

DZD8586 was active with a tolerable safety profile in heavily pretreated, relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Vimseltinib Earns Positive CHMP Recommendation for TGCT

July 28th 2025

The EMA’s CHMP recommended the approval of vimseltinib for symptomatic tenosynovial giant cell tumor.

Perioperative Tislelizumab Receives Positive CHMP Opinion for High-Risk Resectable NSCLC

July 28th 2025

Perioperative tislelizumab received a positive CHMP opinion for resectable non–small cell lung cancer at high risk of recurrence.

CHMP Recommends EU Approval of Vorasidenib for IDH1/2-Mutant Grade 2 Glioma

July 25th 2025

The CHMP has issued a positive opinion for the use of vorasidenib in IDH1/IDH2-mutant grade 2 glioma

Cabozantinib Wins EU Approval for Previously Treated Advanced Pancreatic and Extrapancreatic Neuroendocrine Tumors

July 24th 2025

The European Commission has approved cabozantinib for the treatment of patients with pancreatic and extrapancreatic neuroendocrine tumors.

Belantamab Mafodotin Combos Receive EU, Canadian Approval for R/R Myeloma

July 24th 2025

The European Commission and Health Canada have approved belantamab mafodotin-based combinations for relapsed/refractory multiple myeloma.

Inavolisib Plus Palbociclib/Fulvestrant Gains European Approval in PIK3CA-Mutant, HR+/HER2– Advanced Breast Cancer

July 23rd 2025

The European Commission has approved inavolisib plus palbociclib/fulvestrant in PIK3CA-mutant ER-positive, HER2-negative advanced breast cancer.

Subcutaneous Daratumumab Receives European Commission Approval in Smoldering Myeloma

July 23rd 2025

Subcutaneous daratumumab received EU approval for the treatment of patients with smoldering multiple myeloma at high risk of developing multiple myeloma.

European Commission Approves Ibrutinib in Treatment-Naive, Transplant-Eligible MCL

July 23rd 2025

Ibrutinib has received an expanded indication from the European Commission for the treatment of patients with newly diagnosed MCL eligible for transplant.

SCIB1/iSCIB1+ Vaccines Plus Checkpoint Inhibition Generate Immune Responses in Advanced Melanoma

July 22nd 2025

Among patients with advanced melanoma and the target HLA type—representing 80% of the study population—treatment with iSCIB1+ yielded an ORR of 69%.

EU Grants Conditional Approval of Mirdametinib for NF1-Associated Plexiform Neurofibromas

July 21st 2025

Mirdametinib received conditional EU approval for treating NF1-associated plexiform neurofibromas in patients 2 years of age and older.

European Commission Approves Obe-Cel for Adult R/R B-Cell Precursor Acute Lymphoblastic Leukemia

July 21st 2025

The European Commission approved obe-cel for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.